| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07391774 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… |
Trial sites expanded: 14 -> 18 locations |
| 2026-06-06 | NCT07391774 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… |
Recruitment opened |
| 2026-06-06 | NCT07391774 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… |
Trial sites expanded: 0 -> 14 locations |
| 2026-06-05 | NCT07174336 A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… |
Trial sites expanded: 324 -> 327 locations |
| 2026-06-03 | NCT05827081 Phase IIIb Study of Ribociclib + ET in Early Breast Cancer |
Trial sites expanded: 207 -> 215 locations |
| 2026-05-28 | NCT06492616 A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2… |
Trial sites expanded: 536 -> 541 locations |
| 2026-05-19 | NCT06428396 Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer… |
date change Completion pushed: 2028-10-07 -> 2028-12-25 |
| 2026-05-15 | NCT07174336 A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… |
Trial sites expanded: 317 -> 323 locations |
| 2026-05-14 | NCT06979596 A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) |
Trial sites expanded: 52 -> 55 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced… | Breast Cancer | Recruiting |
| NCT07062965 | A Study to Learn About the Study Medicine Called PF-07248144 in Combination With… | Breast Cancer | Recruiting |
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of… | Breast Cancer, Early Breast Cancer | Recruiting |
| NCT05512364 | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | ER-positive Breast Cancer | Recruiting |
| NCT06380751 | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine… | Advanced Breast Cancer | Recruiting |
| NCT06492616 | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2… | Breast Cancer | Recruiting |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early… | Breast Cancer, Early Breast Cancer | Recruiting |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… | Breast Neoplasms | Recruiting |
| NCT05827081 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Early Breast Cancer | Recruiting |
| NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… | Anatomic Stage II Breast Cancer AJCC v8 | Recruiting |
| NCT01674140 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | Breast Cancer | Active, Not Recruiting |
| NCT02947685 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat… | HER-2 Positive Breast Cancer | Active, Not Recruiting |
| NCT05514054 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early… | Breast Neoplasms | Active, Not Recruiting |
| NCT05306340 | A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With… | Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer | Active, Not Recruiting |
| NCT02115282 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone… | Anatomic Stage III Breast Cancer AJCC v8 | Active, Not Recruiting |
| NCT00310180 | Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have… | Breast Adenocarcinoma | Active, Not Recruiting |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in… | Breast Ductal Carcinoma In Situ | Active, Not Recruiting |
| Phase 2 | |||
| NCT05467891 | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent… | Locoregional Recurrence | Recruiting |
| NCT06179303 | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone… | Anatomic Stage III Breast Cancer AJCC v8 | Recruiting |
| NCT06979596 | A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | Malignant Neoplasm | Recruiting |
| NCT06428396 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer… | Metastatic Breast Cancer | Recruiting |
| NCT06075953 | DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active… | Ductal Carcinoma in Situ | Recruiting |
| NCT05150652 | Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer | Breast Cancer | Active, Not Recruiting |
| NCT06001762 | TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | Breast Cancer | Active, Not Recruiting |
| NCT06105632 | A Study to Learn About the Study Medicine Called PF-07220060 in Combination With… | Advanced or Metastatic Breast Cancer | Active, Not Recruiting |